
<row>
<APPLICATION_ID>7522925</APPLICATION_ID>
<ACTIVITY>R01</ACTIVITY>
<ADMINISTERING_IC>HL</ADMINISTERING_IC>
<APPLICATION_TYPE>1</APPLICATION_TYPE>
<ARRA_FUNDED xsi:nil="true"/>
<BUDGET_START>09/05/2008</BUDGET_START>
<BUDGET_END>08/31/2009</BUDGET_END>
<FOA_NUMBER>PA-07-70</FOA_NUMBER>
<FULL_PROJECT_NUM>1R01HL090863-01A1</FULL_PROJECT_NUM>
<FUNDING_ICs>NHLBI:813665\</FUNDING_ICs>
<FY>2008</FY>
<NIH_SPENDING_CATS>
<CATEGORY>American Indians / Alaska Natives</CATEGORY>
<CATEGORY>Cardiovascular</CATEGORY>
<CATEGORY>Clinical Research</CATEGORY>
<CATEGORY>Clinical Research - Extramural</CATEGORY>
<CATEGORY>Diabetes</CATEGORY>
<CATEGORY>Food Safety</CATEGORY>
<CATEGORY>Heart Disease</CATEGORY>
</NIH_SPENDING_CATS>
<ORG_CITY>BALTIMORE</ORG_CITY>
<ORG_COUNTRY>UNITED STATES</ORG_COUNTRY>
<ORG_DISTRICT>07</ORG_DISTRICT>
<ORG_DUNS>045911138</ORG_DUNS>
<ORG_DEPT>PUBLIC HEALTH &amp;PREV MEDICINE</ORG_DEPT>
<ORG_FIPS>US</ORG_FIPS>
<ORG_STATE>MD</ORG_STATE>
<ORG_ZIPCODE>21218</ORG_ZIPCODE>
<IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME>
<ORG_NAME>JOHNS HOPKINS UNIVERSITY</ORG_NAME>
<PIS>
<PI>
<PI_NAME>NAVAS-ACIEN, ANA </PI_NAME>
<PI_ID>8696712</PI_ID>
</PI>
</PIS>
<PROJECT_TERMS>
<TERM>4H-Imidazol-4-one, 2-amino-1,5-dihydro-1-methyl-</TERM>
<TERM>Aberrant Chromosome</TERM>
<TERM>Abnormalities, Chromosomal</TERM>
<TERM>Active Follow-up</TERM>
<TERM>Affect</TERM>
<TERM>Age</TERM>
<TERM>Age-Years</TERM>
<TERM>Apoplexy</TERM>
<TERM>Arizona</TERM>
<TERM>Arsenates</TERM>
<TERM>Arsenic</TERM>
<TERM>Arsenites</TERM>
<TERM>Articulation</TERM>
<TERM>Assay</TERM>
<TERM>Atheroscleroses</TERM>
<TERM>Atherosclerosis</TERM>
<TERM>Atherosclerotic Cardiovascular Disease</TERM>
<TERM>Benefits and Risks</TERM>
<TERM>Bioassay</TERM>
<TERM>Biologic Assays</TERM>
<TERM>Biological</TERM>
<TERM>Biological Assay</TERM>
<TERM>Biotransformation</TERM>
<TERM>Bladder</TERM>
<TERM>Blood</TERM>
<TERM>Blood Plasma</TERM>
<TERM>CREA</TERM>
<TERM>Cacodylate</TERM>
<TERM>Cardiovascular</TERM>
<TERM>Cardiovascular Body System</TERM>
<TERM>Cardiovascular Diseases</TERM>
<TERM>Cardiovascular system</TERM>
<TERM>Cardiovascular system (all sites)</TERM>
<TERM>Cerebral Stroke</TERM>
<TERM>Cerebrovascular Apoplexy</TERM>
<TERM>Cerebrovascular Stroke</TERM>
<TERM>Cerebrovascular accident</TERM>
<TERM>Chromatography, High Performance Liquid</TERM>
<TERM>Chromatography, High Pressure Liquid</TERM>
<TERM>Chromatography, High Speed Liquid</TERM>
<TERM>Chromosomal Aberrations</TERM>
<TERM>Chromosomal Alterations</TERM>
<TERM>Chromosome Aberrations</TERM>
<TERM>Chromosome Alterations</TERM>
<TERM>Chromosome Anomalies</TERM>
<TERM>Chromosome abnormality</TERM>
<TERM>Chronic</TERM>
<TERM>Clinical</TERM>
<TERM>Cohort Studies</TERM>
<TERM>Communities</TERM>
<TERM>Comorbidity</TERM>
<TERM>Concurrent Studies</TERM>
<TERM>Coronary Disease</TERM>
<TERM>Coronary heart disease</TERM>
<TERM>Coupled</TERM>
<TERM>Cox Proportional Hazards Models</TERM>
<TERM>Creatinine</TERM>
<TERM>Cytogenetic Aberrations</TERM>
<TERM>Cytogenetic Abnormalities</TERM>
<TERM>Data</TERM>
<TERM>Development</TERM>
<TERM>Diabetes Mellitus</TERM>
<TERM>Dimethylarsinate</TERM>
<TERM>Disease</TERM>
<TERM>Disease regression</TERM>
<TERM>Disorder</TERM>
<TERM>Dose</TERM>
<TERM>ENPT</TERM>
<TERM>Elements</TERM>
<TERM>End Point</TERM>
<TERM>EndPointCode</TERM>
<TERM>Endpoints</TERM>
<TERM>Epidemiologic Research</TERM>
<TERM>Epidemiologic Studies</TERM>
<TERM>Epidemiological Studies</TERM>
<TERM>Epidemiology Research</TERM>
<TERM>Ethnic group</TERM>
<TERM>Evaluation</TERM>
<TERM>Exposure to</TERM>
<TERM>Formosa</TERM>
<TERM>Freezing</TERM>
<TERM>Funding</TERM>
<TERM>General Population</TERM>
<TERM>General Public</TERM>
<TERM>Generations</TERM>
<TERM>HPLC</TERM>
<TERM>Heart</TERM>
<TERM>High Pressure Liquid Chromatography</TERM>
<TERM>High Prevalence</TERM>
<TERM>Human</TERM>
<TERM>Human, General</TERM>
<TERM>Incidence</TERM>
<TERM>Individual</TERM>
<TERM>Institutes</TERM>
<TERM>Intermediary Metabolism</TERM>
<TERM>Joints</TERM>
<TERM>Laboratories</TERM>
<TERM>Lesion</TERM>
<TERM>Life Style</TERM>
<TERM>Lifestyle</TERM>
<TERM>Lung</TERM>
<TERM>METBL</TERM>
<TERM>Malignant Skin Neoplasm</TERM>
<TERM>Malignant Tumor of the Skin</TERM>
<TERM>Man (Taxonomy)</TERM>
<TERM>Man, Modern</TERM>
<TERM>Mass Spectrum</TERM>
<TERM>Mass Spectrum Analysis</TERM>
<TERM>Measurement</TERM>
<TERM>Measures</TERM>
<TERM>Medical</TERM>
<TERM>Melanoma and Non-Melanoma Skin Cancer</TERM>
<TERM>Metabolic Biotransformation</TERM>
<TERM>Metabolic Pathway</TERM>
<TERM>Metabolic Processes</TERM>
<TERM>Metabolism</TERM>
<TERM>Methylation</TERM>
<TERM>Modeling</TERM>
<TERM>Modification</TERM>
<TERM>Morbidity</TERM>
<TERM>Morbidity - disease rate</TERM>
<TERM>Mortality</TERM>
<TERM>Mortality Vital Statistics</TERM>
<TERM>National Research Council</TERM>
<TERM>National Research Council (U.S.)</TERM>
<TERM>Native Americans</TERM>
<TERM>Oklahoma</TERM>
<TERM>Organ System, Cardiovascular</TERM>
<TERM>Outcome</TERM>
<TERM>Outcome Study</TERM>
<TERM>Participant</TERM>
<TERM>Pattern</TERM>
<TERM>Peripheral</TERM>
<TERM>Peripheral arterial disease</TERM>
<TERM>Persons</TERM>
<TERM>Photometry/Spectrum Analysis, Mass</TERM>
<TERM>Plasma</TERM>
<TERM>Population</TERM>
<TERM>Prevalence</TERM>
<TERM>Process</TERM>
<TERM>Protein Methylation</TERM>
<TERM>Public Health</TERM>
<TERM>Range</TERM>
<TERM>Rate</TERM>
<TERM>Recommendation</TERM>
<TERM>Recruitment Activity</TERM>
<TERM>Regression</TERM>
<TERM>Republic of China</TERM>
<TERM>Research</TERM>
<TERM>Research Design</TERM>
<TERM>Research Priority</TERM>
<TERM>Research Specimen</TERM>
<TERM>Respiratory System, Lung</TERM>
<TERM>Reticuloendothelial System, Blood</TERM>
<TERM>Reticuloendothelial System, Serum, Plasma</TERM>
<TERM>Risk</TERM>
<TERM>Risk Estimate</TERM>
<TERM>Risk Factors</TERM>
<TERM>Role</TERM>
<TERM>Rural Community</TERM>
<TERM>Rural Population</TERM>
<TERM>Sampling</TERM>
<TERM>Sampling Studies</TERM>
<TERM>Serum, Plasma</TERM>
<TERM>Severities</TERM>
<TERM>Skin</TERM>
<TERM>Skin Cancer</TERM>
<TERM>Skin Cancer, Including Melanoma</TERM>
<TERM>Smoker</TERM>
<TERM>Smoking</TERM>
<TERM>Smoking Status</TERM>
<TERM>South Dakota</TERM>
<TERM>Specimen</TERM>
<TERM>Spectrometry, Mass</TERM>
<TERM>Spectroscopy, Mass</TERM>
<TERM>Spectrum Analyses, Mass</TERM>
<TERM>Spectrum Analysis, Mass</TERM>
<TERM>Standards</TERM>
<TERM>Standards of Weights and Measures</TERM>
<TERM>Stroke</TERM>
<TERM>Study Type</TERM>
<TERM>Study, Outcome</TERM>
<TERM>Sum</TERM>
<TERM>Taiwan</TERM>
<TERM>Toxic effect</TERM>
<TERM>Toxicities</TERM>
<TERM>Urinary System, Bladder</TERM>
<TERM>Urinary System, Urine</TERM>
<TERM>Urine</TERM>
<TERM>Vascular Accident, Brain</TERM>
<TERM>Vascular, Heart</TERM>
<TERM>Visit</TERM>
<TERM>atheromatosis</TERM>
<TERM>atherosclerotic vascular disease</TERM>
<TERM>base</TERM>
<TERM>brain attack</TERM>
<TERM>cardiovascular disease risk</TERM>
<TERM>cardiovascular disorder</TERM>
<TERM>cardiovascular disorder risk</TERM>
<TERM>cardiovascular risk</TERM>
<TERM>cardiovascular risk factor</TERM>
<TERM>cerebral vascular accident</TERM>
<TERM>circulatory system</TERM>
<TERM>coronary disorder</TERM>
<TERM>design</TERM>
<TERM>designing</TERM>
<TERM>diabetes</TERM>
<TERM>diabetes risk</TERM>
<TERM>disease/disorder</TERM>
<TERM>drinking water</TERM>
<TERM>follow-up</TERM>
<TERM>member</TERM>
<TERM>methylarsonate</TERM>
<TERM>prospective</TERM>
<TERM>public health medicine (field)</TERM>
<TERM>pulmonary</TERM>
<TERM>recruit</TERM>
<TERM>response</TERM>
<TERM>social role</TERM>
<TERM>socioeconomic</TERM>
<TERM>socioeconomically</TERM>
<TERM>socioeconomics</TERM>
<TERM>stroke</TERM>
<TERM>study design</TERM>
<TERM>urinary bladder</TERM>
<TERM>vapor</TERM>
</PROJECT_TERMS>
<PROJECT_TITLE>Arsenic Exposure, Cardiovascular Disease and Diabetes in Native Americans</PROJECT_TITLE>
<PROJECT_START>09/05/2008</PROJECT_START>
<PROJECT_END>08/31/2012</PROJECT_END>
<PHR xsi:nil="true"/>
<SERIAL_NUMBER>90863</SERIAL_NUMBER>
<STUDY_SECTION>CASE</STUDY_SECTION>
<STUDY_SECTION_NAME>Cardiovascular and Sleep Epidemiology Study Section</STUDY_SECTION_NAME>
<SUPPORT_YEAR>1</SUPPORT_YEAR>
<SUFFIX>A1</SUFFIX>
<SUBPROJECT_ID xsi:nil="true"/>
<TOTAL_COST>813665</TOTAL_COST>
<TOTAL_COST_SUB_PROJECT xsi:nil="true"/>
<CORE_PROJECT_NUM>R01HL090863</CORE_PROJECT_NUM>
<CFDA_CODE>837</CFDA_CODE>
<PROGRAM_OFFICER_NAME>EDWARDS, MICHAEL W.</PROGRAM_OFFICER_NAME>
<ED_INST_TYPE>SCHOOLS OF PUBLIC HEALTH</ED_INST_TYPE>
<AWARD_NOTICE_DATE>2008-09-05</AWARD_NOTICE_DATE>
</row>

<row>
<APPLICATION_ID>7465832</APPLICATION_ID>
<ACTIVITY>R01</ACTIVITY>
<ADMINISTERING_IC>HL</ADMINISTERING_IC>
<APPLICATION_TYPE>1</APPLICATION_TYPE>
<ARRA_FUNDED xsi:nil="true"/>
<BUDGET_START>04/15/2008</BUDGET_START>
<BUDGET_END>03/31/2009</BUDGET_END>
<FOA_NUMBER>PA-07-70</FOA_NUMBER>
<FULL_PROJECT_NUM>1R01HL089332-01A1</FULL_PROJECT_NUM>
<FUNDING_ICs>NHLBI:419875\</FUNDING_ICs>
<FY>2008</FY>
<NIH_SPENDING_CATS>
<CATEGORY>Clinical Research</CATEGORY>
<CATEGORY>Clinical Research - Extramural</CATEGORY>
<CATEGORY>Digestive Diseases</CATEGORY>
<CATEGORY>Emerging Infectious Diseases</CATEGORY>
<CATEGORY>Food Safety</CATEGORY>
<CATEGORY>Hematology</CATEGORY>
<CATEGORY>Infectious Diseases</CATEGORY>
<CATEGORY>Kidney Disease</CATEGORY>
<CATEGORY>Kidney and Urologic Diseases inc. Nephritis</CATEGORY>
</NIH_SPENDING_CATS>
<ORG_CITY>BOSTON</ORG_CITY>
<ORG_COUNTRY>UNITED STATES</ORG_COUNTRY>
<ORG_DISTRICT>09</ORG_DISTRICT>
<ORG_DUNS xsi:nil="true"/>
<ORG_DEPT xsi:nil="true"/>
<ORG_FIPS>US</ORG_FIPS>
<ORG_STATE>MA</ORG_STATE>
<ORG_ZIPCODE>02199</ORG_ZIPCODE>
<IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME>
<ORG_NAME>MASSACHUSETTS GENERAL HOSPITAL</ORG_NAME>
<PIS>
<PI>
<PI_NAME>GRABOWSKI, ERIC FRANKLIN</PI_NAME>
<PI_ID>1893595</PI_ID>
</PI>
</PIS>
<PROJECT_TERMS>
<TERM>Adhesion Molecule</TERM>
<TERM>Adhesions</TERM>
<TERM>Adhesives</TERM>
<TERM>Affect</TERM>
<TERM>Anti-Phospholipid Antibodies</TERM>
<TERM>Antibodies</TERM>
<TERM>Antiphospholipid Antibodies</TERM>
<TERM>Apoptosis</TERM>
<TERM>Apoptosis Pathway</TERM>
<TERM>Appearance</TERM>
<TERM>Arteries</TERM>
<TERM>Arterioles</TERM>
<TERM>Attention</TERM>
<TERM>Bacterial Toxins</TERM>
<TERM>Beds</TERM>
<TERM>Binding</TERM>
<TERM>Binding (Molecular Function)</TERM>
<TERM>Bizzozero&apos;s corpuscle/cell</TERM>
<TERM>Blood</TERM>
<TERM>Blood Coagulation Factor I</TERM>
<TERM>Blood Coagulation Factor III</TERM>
<TERM>Blood Coagulation Factor One</TERM>
<TERM>Blood Coagulation Factor VII, Activated</TERM>
<TERM>Blood Factor One</TERM>
<TERM>Blood Platelets</TERM>
<TERM>Blood Vessels</TERM>
<TERM>Blood flow</TERM>
<TERM>Blood granulocytic cell</TERM>
<TERM>Blood leukocyte</TERM>
<TERM>Body Tissues</TERM>
<TERM>CD142 Antigens</TERM>
<TERM>CD54 (ICAM 1)</TERM>
<TERM>CD54 Antigens</TERM>
<TERM>CD61 Antigens</TERM>
<TERM>CD62P Antigens</TERM>
<TERM>Cardiac artery</TERM>
<TERM>Cell Adhesion Molecules</TERM>
<TERM>Cell Death, Programmed</TERM>
<TERM>Cell membrane</TERM>
<TERM>Cell secretion</TERM>
<TERM>Cell surface</TERM>
<TERM>Cells</TERM>
<TERM>Cellular Secretion</TERM>
<TERM>Cellular injury</TERM>
<TERM>Cessation of life</TERM>
<TERM>Childhood</TERM>
<TERM>Cleaved cell</TERM>
<TERM>Clotting</TERM>
<TERM>Coagulation</TERM>
<TERM>Coagulation Factor I</TERM>
<TERM>Coagulation Factor III</TERM>
<TERM>Coagulation Factor One</TERM>
<TERM>Coagulation Factor VIIa</TERM>
<TERM>Coagulation Process</TERM>
<TERM>Coagulin</TERM>
<TERM>Collagen</TERM>
<TERM>Coma</TERM>
<TERM>Comatose</TERM>
<TERM>Condition</TERM>
<TERM>Coronary artery</TERM>
<TERM>Culture Media</TERM>
<TERM>Cytoplasmic Membrane</TERM>
<TERM>DIF</TERM>
<TERM>Death</TERM>
<TERM>Deetjeen&apos;s body</TERM>
<TERM>Deposit</TERM>
<TERM>Deposition</TERM>
<TERM>Disease</TERM>
<TERM>Disorder</TERM>
<TERM>Disruption</TERM>
<TERM>Down-Regulation</TERM>
<TERM>Down-Regulation (Physiology)</TERM>
<TERM>Downregulation</TERM>
<TERM>E coli</TERM>
<TERM>EHEC</TERM>
<TERM>EHEC, Escherichia coli</TERM>
<TERM>Endopeptidases</TERM>
<TERM>Endothelial Cells</TERM>
<TERM>Endothelium</TERM>
<TERM>Endothelium, Vascular</TERM>
<TERM>Enhancers</TERM>
<TERM>Ensure</TERM>
<TERM>Enterohemorrhagic E coli</TERM>
<TERM>Enterohemorrhagic E. coli</TERM>
<TERM>Enterohemorrhagic E.coli</TERM>
<TERM>Enterohemorrhagic Escherichia coli</TERM>
<TERM>Enterohemorrhagic strain of E coli</TERM>
<TERM>Enterohemorrhagic strain of E. coli</TERM>
<TERM>Enterohemorrhagic strain of Escherichia coli</TERM>
<TERM>Epidemic</TERM>
<TERM>Epithelial Cells</TERM>
<TERM>Escherichia coli</TERM>
<TERM>Escherichia coli EHEC</TERM>
<TERM>Esteroproteases</TERM>
<TERM>Extracellular Matrix, Integrins</TERM>
<TERM>Factor I</TERM>
<TERM>Factor III</TERM>
<TERM>Factor One</TERM>
<TERM>Factor VII, Activated</TERM>
<TERM>Factor VIIa</TERM>
<TERM>Fibrin</TERM>
<TERM>Fibrinogen</TERM>
<TERM>Fostering</TERM>
<TERM>GMP-140</TERM>
<TERM>GPI</TERM>
<TERM>GPIIIa</TERM>
<TERM>Gasser&apos;s Syndrome</TERM>
<TERM>Glass</TERM>
<TERM>Glomerular Procoagulant Activity</TERM>
<TERM>Gly-PtdIns</TERM>
<TERM>Glycoprotein ICAM 1 (human clone pHRVr1 deblocked protein moiety reduced)</TERM>
<TERM>Glycosyl-Phosphatidylinositol</TERM>
<TERM>Glycosylated Phosphatidylinositols</TERM>
<TERM>Glycosylphosphatidylinositols</TERM>
<TERM>Granular Leukocytes</TERM>
<TERM>Granulocytic cell</TERM>
<TERM>Hayem&apos;s elementary corpuscle</TERM>
<TERM>Heart artery</TERM>
<TERM>Hemolytic-Uremic Syndrome</TERM>
<TERM>Hour</TERM>
<TERM>Human</TERM>
<TERM>Human, General</TERM>
<TERM>ICAM-1</TERM>
<TERM>Image</TERM>
<TERM>Impairment</TERM>
<TERM>Incubated</TERM>
<TERM>Inflammatory</TERM>
<TERM>Integrin beta3</TERM>
<TERM>Integrins</TERM>
<TERM>Intercellular adhesion molecule 1</TERM>
<TERM>Interruption</TERM>
<TERM>Intestinal</TERM>
<TERM>Intestines</TERM>
<TERM>Kidney</TERM>
<TERM>Kidney Failure</TERM>
<TERM>Kidney Insufficiency</TERM>
<TERM>LECAM-3</TERM>
<TERM>Lead</TERM>
<TERM>Leukocytes</TERM>
<TERM>Link</TERM>
<TERM>Localized</TERM>
<TERM>Man (Taxonomy)</TERM>
<TERM>Man, Modern</TERM>
<TERM>Marrow leukocyte</TERM>
<TERM>Marrow platelet</TERM>
<TERM>Measurement</TERM>
<TERM>Mediating</TERM>
<TERM>Membrane</TERM>
<TERM>Messenger RNA</TERM>
<TERM>Microscopy, Video</TERM>
<TERM>Modeling</TERM>
<TERM>Molecular Interaction</TERM>
<TERM>Necrosis</TERM>
<TERM>Necrotic</TERM>
<TERM>Organ</TERM>
<TERM>OxLDL</TERM>
<TERM>P-Selectin</TERM>
<TERM>Pathway interactions</TERM>
<TERM>Pb element</TERM>
<TERM>Peptidases</TERM>
<TERM>Peptide Hydrolases</TERM>
<TERM>Peptide Peptidohydrolases</TERM>
<TERM>Phenotype</TERM>
<TERM>Phosphatides</TERM>
<TERM>Phosphatidylserines</TERM>
<TERM>Phospholipids</TERM>
<TERM>Plasma Membrane</TERM>
<TERM>Platelet GPIIIa</TERM>
<TERM>Platelet Glycoprotein IIIa</TERM>
<TERM>Platelet Membrane Glycoprotein IIIa</TERM>
<TERM>Platelet alpha-Granule Membrane Protein</TERM>
<TERM>Platelets</TERM>
<TERM>Play</TERM>
<TERM>Process</TERM>
<TERM>Production</TERM>
<TERM>Proteases</TERM>
<TERM>Proteinases</TERM>
<TERM>Proteins</TERM>
<TERM>Proteolytic Enzyme</TERM>
<TERM>Proteolytic Enzymes</TERM>
<TERM>Prothrombinase</TERM>
<TERM>Public Health</TERM>
<TERM>RNA, Messenger</TERM>
<TERM>Range</TERM>
<TERM>Rate</TERM>
<TERM>Receptor Protein</TERM>
<TERM>Recombinants</TERM>
<TERM>Relative</TERM>
<TERM>Relative (related person)</TERM>
<TERM>Renal Failure</TERM>
<TERM>Renal Insufficiency</TERM>
<TERM>Reporting</TERM>
<TERM>Resolution</TERM>
<TERM>Reticuloendothelial System, Blood</TERM>
<TERM>Reticuloendothelial System, Leukocytes</TERM>
<TERM>Reticuloendothelial System, Platelets</TERM>
<TERM>Ristocetin Cofactor</TERM>
<TERM>Ristocetin-Willebrand Factor</TERM>
<TERM>Role</TERM>
<TERM>Route</TERM>
<TERM>SLT-I</TERM>
<TERM>SLTI</TERM>
<TERM>STEC</TERM>
<TERM>Seizures</TERM>
<TERM>Selectins</TERM>
<TERM>Serine Phosphoglycerides</TERM>
<TERM>Shiga Toxin</TERM>
<TERM>Shiga Toxin 1</TERM>
<TERM>Shiga toxin-producing E coli</TERM>
<TERM>Shiga toxin-producing E. coli</TERM>
<TERM>Shiga toxin-producing E.coli</TERM>
<TERM>Shiga toxin-producing Escherichia coli</TERM>
<TERM>Shiga-Like Toxin I</TERM>
<TERM>Shigella Cytotoxin</TERM>
<TERM>Shigella Toxin</TERM>
<TERM>Site</TERM>
<TERM>Slide</TERM>
<TERM>Stability, mRNA</TERM>
<TERM>Stress</TERM>
<TERM>Structure of arteriole</TERM>
<TERM>Stx Protein</TERM>
<TERM>Stx Protein, Shigella dysenteria</TERM>
<TERM>Stx1 Protein</TERM>
<TERM>Surface</TERM>
<TERM>System</TERM>
<TERM>System, LOINC Axis 4</TERM>
<TERM>TFPI</TERM>
<TERM>TNF</TERM>
<TERM>TNF A</TERM>
<TERM>TNF gene</TERM>
<TERM>TNFSF2</TERM>
<TERM>Testing</TERM>
<TERM>Therapeutic</TERM>
<TERM>Therapeutic Intervention</TERM>
<TERM>Thick</TERM>
<TERM>Thickness</TERM>
<TERM>Thrombase</TERM>
<TERM>Thrombin</TERM>
<TERM>Thrombocytes</TERM>
<TERM>Thromboplastin</TERM>
<TERM>Thrombosis</TERM>
<TERM>Thrombus</TERM>
<TERM>Tissue Factor</TERM>
<TERM>Tissue Factor Procoagulant</TERM>
<TERM>Tissue Thromboplastin</TERM>
<TERM>Tissues</TERM>
<TERM>Toxin</TERM>
<TERM>Tumor Necrosis Factor Gene</TERM>
<TERM>United States</TERM>
<TERM>Up-Regulation</TERM>
<TERM>Up-Regulation (Physiology)</TERM>
<TERM>Upregulation</TERM>
<TERM>Urinary System, Kidney</TERM>
<TERM>Urothromboplastin</TERM>
<TERM>VT1 Cytotoxin</TERM>
<TERM>Vascular Endothelium</TERM>
<TERM>Vero Cytotoxin VT1</TERM>
<TERM>Verocytotoxin 1</TERM>
<TERM>Verotoxin I</TERM>
<TERM>Video Microscopy</TERM>
<TERM>Videomicrography</TERM>
<TERM>Videomicroscopy</TERM>
<TERM>Vitronectin Receptors</TERM>
<TERM>WHBLOOD</TERM>
<TERM>White Blood Cells</TERM>
<TERM>White Cell</TERM>
<TERM>Whole Blood</TERM>
<TERM>Work</TERM>
<TERM>arteriole</TERM>
<TERM>beta(3) Integrin</TERM>
<TERM>bowel</TERM>
<TERM>cell adhesion protein</TERM>
<TERM>cell damage</TERM>
<TERM>cell injury</TERM>
<TERM>cleaved</TERM>
<TERM>cytokine</TERM>
<TERM>digital</TERM>
<TERM>disease/disorder</TERM>
<TERM>experiment</TERM>
<TERM>experimental research</TERM>
<TERM>experimental study</TERM>
<TERM>exposed human population</TERM>
<TERM>fibrinogenase</TERM>
<TERM>food-born</TERM>
<TERM>food-borne</TERM>
<TERM>foodborn</TERM>
<TERM>foodborne</TERM>
<TERM>gene product</TERM>
<TERM>granulocyte</TERM>
<TERM>growth media</TERM>
<TERM>heavy metal Pb</TERM>
<TERM>heavy metal lead</TERM>
<TERM>human exposure</TERM>
<TERM>imaging</TERM>
<TERM>in vitro Model</TERM>
<TERM>in vivo</TERM>
<TERM>inhibitor</TERM>
<TERM>inhibitor/antagonist</TERM>
<TERM>intervention therapy</TERM>
<TERM>mRNA</TERM>
<TERM>mRNA Stability</TERM>
<TERM>membrane structure</TERM>
<TERM>monolayer</TERM>
<TERM>ox-LDL</TERM>
<TERM>oxidized LDL</TERM>
<TERM>oxidized low density lipoprotein</TERM>
<TERM>pathway</TERM>
<TERM>pediatric</TERM>
<TERM>plasmalemma</TERM>
<TERM>protease</TERM>
<TERM>proteinase</TERM>
<TERM>public health medicine (field)</TERM>
<TERM>receptor</TERM>
<TERM>renal</TERM>
<TERM>research study</TERM>
<TERM>shear stress</TERM>
<TERM>social role</TERM>
<TERM>thrombocyte/platelet</TERM>
<TERM>tissue factor pathway inhibitor</TERM>
<TERM>vWF</TERM>
<TERM>vascular</TERM>
<TERM>von Willebrand Factor</TERM>
<TERM>von Willebrand Protein</TERM>
<TERM>white blood cell</TERM>
<TERM>white blood corpuscle</TERM>
</PROJECT_TERMS>
<PROJECT_TITLE>Tissue Factor, Flow, and Platelet Adhesion/Aggregation on Activated Endothelium</PROJECT_TITLE>
<PROJECT_START>04/15/2008</PROJECT_START>
<PROJECT_END>03/31/2012</PROJECT_END>
<PHR xsi:nil="true"/>
<SERIAL_NUMBER>89332</SERIAL_NUMBER>
<STUDY_SECTION>BTSS</STUDY_SECTION>
<STUDY_SECTION_NAME>Bioengineering, Technology and Surgical Sciences Study Section</STUDY_SECTION_NAME>
<SUPPORT_YEAR>1</SUPPORT_YEAR>
<SUFFIX>A1</SUFFIX>
<SUBPROJECT_ID xsi:nil="true"/>
<TOTAL_COST>419875</TOTAL_COST>
<TOTAL_COST_SUB_PROJECT xsi:nil="true"/>
<CORE_PROJECT_NUM>R01HL089332</CORE_PROJECT_NUM>
<CFDA_CODE>837</CFDA_CODE>
<PROGRAM_OFFICER_NAME>LINK, REBECCA P.</PROGRAM_OFFICER_NAME>
<ED_INST_TYPE xsi:nil="true"/>
<AWARD_NOTICE_DATE>2008-04-14</AWARD_NOTICE_DATE>
</row>

